Figure 1: Ranibizumab is a recombinant humanized monoclonal antibody fragment. Bevacizumab is a recombinant humanized IgG antibody. Both bind to and inhibit all biologically active forms of VEGF-A and are derived from the same mouse monoclonal antibody. Ranibizumab has been genetically engineered to bind with higher affinity than bevacizumab (see [8]).